SYNCOMFPharmaceuticals
Syncom Formulations India Ltd — Profit & Loss Statement
₹10.30
-5.36%
Syncom Formulations India Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Normalized Income | 49.43 Cr | 25.33 Cr | 19.93 Cr | 19.76 Cr | — |
| Net Income From Continuing And Discontinued Operation | 49.43 Cr | 25.31 Cr | 20.07 Cr | 19.79 Cr | — |
| Total Expenses | 416.07 Cr | 238.46 Cr | 206.03 Cr | 200.55 Cr | — |
| Diluted Average Shares | 86.73 Cr | 74.45 Cr | 92.85 Cr | 87.32 Cr | — |
| Basic Average Shares | 86.73 Cr | 74.45 Cr | 92.85 Cr | 81.69 Cr | — |
| Diluted EPS | 0.57 | 0.34 | 0.22 | 0.24 | — |
| Basic EPS | 0.57 | 0.34 | 0.22 | 0.26 | — |
| Diluted NI Availto Com Stockholders | 49.43 Cr | 25.31 Cr | 20.07 Cr | 19.79 Cr | — |
| Net Income Common Stockholders | 49.43 Cr | 25.31 Cr | 20.07 Cr | 19.79 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 49.43 Cr | 25.31 Cr | 20.07 Cr | 19.79 Cr | — |
| Net Income Including Noncontrolling Interests | 49.43 Cr | 25.31 Cr | 20.07 Cr | 19.79 Cr | — |
| Net Income Discontinuous Operations | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income Continuous Operations | 49.43 Cr | 25.31 Cr | 20.07 Cr | 19.79 Cr | — |
| Tax Provision | 16.08 Cr | 8.64 Cr | 6.50 Cr | 6.39 Cr | — |
| Pretax Income | 65.51 Cr | 33.95 Cr | 26.57 Cr | 26.18 Cr | — |
| Other Non Operating Income Expenses | 17.43 Cr | 13.53 Cr | 4.52 Cr | 3.66 Cr | — |
| Special Income Charges | 58000.00 | -0.02 Cr | 0.01 Cr | 0.02 Cr | — |
| Net Non Operating Interest Income Expense | -0.86 Cr | -4.47 Cr | 1.32 Cr | 2.00 Cr | — |
| Interest Expense Non Operating | 0.86 Cr | 4.47 Cr | 3.19 Cr | 1.83 Cr | — |
| Operating Income | 48.94 Cr | 24.93 Cr | 16.45 Cr | 17.27 Cr | — |
| Operating Expense | 108.74 Cr | 81.58 Cr | 56.18 Cr | 53.70 Cr | — |
| Other Operating Expenses | 51.37 Cr | 41.80 Cr | 2.76 Cr | 2.34 Cr | — |
| Depreciation And Amortization In Income Statement | 5.19 Cr | 4.72 Cr | 4.54 Cr | 3.95 Cr | — |
| Depreciation Income Statement | 5.19 Cr | 4.72 Cr | 4.54 Cr | 3.95 Cr | — |
| Gross Profit | 157.68 Cr | 106.51 Cr | 72.64 Cr | 70.97 Cr | — |
| Cost Of Revenue | 307.34 Cr | 156.88 Cr | 149.85 Cr | 146.85 Cr | — |
| Total Revenue | 465.01 Cr | 263.39 Cr | 222.49 Cr | 217.82 Cr | — |
| Operating Revenue | 465.01 Cr | 263.39 Cr | 222.49 Cr | 217.82 Cr | — |
| Tax Effect Of Unusual Items | 14234.34 | -60809.74 | 0.04 Cr | 99773.82 | — |
| Tax Rate For Calcs | 0.25 | 0.25 | 0.24 | 0.24 | — |
| Normalized EBITDA | 71.57 Cr | 43.17 Cr | 34.12 Cr | 31.91 Cr | — |
| Total Unusual Items | 58000.00 | -0.02 Cr | 0.18 Cr | 0.04 Cr | — |
| Total Unusual Items Excluding Goodwill | 58000.00 | -0.02 Cr | 0.18 Cr | 0.04 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 49.43 Cr | 25.31 Cr | 20.07 Cr | 19.79 Cr | — |
| Reconciled Depreciation | 5.19 Cr | 4.72 Cr | 4.54 Cr | 3.95 Cr | — |
| Reconciled Cost Of Revenue | 307.34 Cr | 156.88 Cr | 149.85 Cr | 146.85 Cr | — |
| EBITDA | 71.57 Cr | 43.15 Cr | 34.30 Cr | 31.95 Cr | — |
| EBIT | 66.38 Cr | 38.43 Cr | 29.76 Cr | 28.00 Cr | — |
| Net Interest Income | -0.86 Cr | -4.47 Cr | 1.32 Cr | 2.00 Cr | — |
| Interest Expense | 0.86 Cr | 4.47 Cr | 3.19 Cr | 1.83 Cr | — |
| Rent Expense Supplemental | — | 0.70 Cr | 0.97 Cr | 0.95 Cr | 0.82 Cr |
| Other Special Charges | — | 0.02 Cr | -0.01 Cr | -0.02 Cr | -0.03 Cr |
| Total Other Finance Cost | — | 0.36 Cr | 0.21 Cr | 0.10 Cr | 0.28 Cr |
| Interest Income Non Operating | — | 5.52 Cr | 4.72 Cr | 3.93 Cr | 1.35 Cr |
| Selling General And Administration | — | 29.46 Cr | 25.03 Cr | 27.45 Cr | 17.72 Cr |
| Selling And Marketing Expense | — | 27.26 Cr | 23.32 Cr | 26.40 Cr | 16.90 Cr |
| General And Administrative Expense | — | 2.20 Cr | 1.71 Cr | 1.05 Cr | 0.82 Cr |
| Rent And Landing Fees | — | 0.56 Cr | 0.85 Cr | 0.83 Cr | 0.73 Cr |
| Interest Income | — | 5.52 Cr | 4.72 Cr | 3.93 Cr | 1.35 Cr |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Syncom Formulations India Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.